14.96
price down icon4.29%   -0.67
after-market アフターアワーズ: 14.96
loading
前日終値:
$15.63
開ける:
$15.03
24時間の取引高:
84,615
Relative Volume:
1.37
時価総額:
$2.61B
収益:
$630.20M
当期純損益:
$37.73M
株価収益率:
74.80
EPS:
0.2
ネットキャッシュフロー:
$-17.44M
1週間 パフォーマンス:
-5.79%
1か月 パフォーマンス:
-15.05%
6か月 パフォーマンス:
-10.04%
1年 パフォーマンス:
-13.63%
1日の値動き範囲:
Value
$14.88
$15.14
1週間の範囲:
Value
$14.88
$16.30
52週間の値動き範囲:
Value
$11.51
$21.50

Hutchmed China Limited Adr Stock (HCM) Company Profile

Name
名前
Hutchmed China Limited Adr
Name
セクター
Healthcare (1146)
Name
電話
-
Name
住所
-
Name
職員
1,811
Name
Twitter
@hchimed
Name
次回の収益日
2025-03-19
Name
最新のSEC提出書
Name
HCM's Discussions on Twitter

HCM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
HCM
Hutchmed China Limited Adr
14.96 2.69B 630.20M 37.73M -17.44M 0.20
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.37 68.60B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.86 46.99B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.71 43.17B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.05 20.82B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.35 13.98B 2.99B 1.21B 1.13B 25.06

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-13 ダウングレード HSBC Securities Buy → Hold
2023-11-24 アップグレード Deutsche Bank Hold → Buy
2022-05-04 ダウングレード Deutsche Bank Buy → Hold
2021-09-22 ダウングレード Goldman Buy → Neutral
2021-08-03 開始されました Jefferies Buy
2020-10-02 開始されました Deutsche Bank Buy
2020-03-13 開始されました Cantor Fitzgerald Overweight
2020-02-20 開始されました Goldman Buy
2019-11-19 開始されました CLSA Buy
2019-10-23 繰り返されました BofA/Merrill Buy
2019-07-05 開始されました Macquarie Outperform
すべてを表示

Hutchmed China Limited Adr (HCM) 最新ニュース

pulisher
Aug 24, 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewswire Inc.

Aug 24, 2025
pulisher
Aug 19, 2025

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewswire

Aug 19, 2025
pulisher
Aug 19, 2025

Best Momentum Stock to Buy for August 19th - The Globe and Mail

Aug 19, 2025
pulisher
Aug 19, 2025

Best Momentum Stock To Buy For August 19th - Barchart.com

Aug 19, 2025
pulisher
Aug 19, 2025

How to build a custom watchlist for HUTCHMED (China) Limited Depositary Receipt2025 Price Action Summary & Verified Momentum Stock Ideas - Newser

Aug 19, 2025
pulisher
Aug 11, 2025

BOCOMI Lowers HUTCHMED's TP to HKD37.6; Rating Kept Buy - AASTOCKS.com

Aug 11, 2025
pulisher
Aug 09, 2025

Will HUTCHMED (China) Limited Depositary Receipt bounce back from current supportFree Oversold Recovery Opportunity Stocks - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Trend analysis for HUTCHMED (China) Limited Depositary Receipt this weekStock Holding Strategy Long-Term Summary Sheet - Newser

Aug 08, 2025
pulisher
Jul 14, 2025

Carvana Co. (NYSE:CVNA) Major Shareholder Sells $35,236,000.00 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Crossmark Global Holdings Inc. Sells 414 Shares of Morningstar, Inc. (NASDAQ:MORN) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

6,121 Shares in John Hancock Multifactor Large Cap ETF (NYSEARCA:JHML) Bought by Crossmark Global Holdings Inc. - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Concurrent Investment Advisors LLC Acquires New Holdings in ADMA Biologics Inc (NASDAQ:ADMA) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Crossmark Global Holdings Inc. Has $356,000 Holdings in Nordson Corporation (NASDAQ:NDSN) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Buenaventura Mining (NYSE:BVN) vs. Hochschild Mining (OTCMKTS:HCHDF) Head-To-Head Review - Defense World

Jul 14, 2025
pulisher
Jul 03, 2025

Coinbase Global, Inc. (NASDAQ:COIN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Jul 03, 2025
pulisher
Jun 30, 2025

HUTCHMED Gains China Approval for Innovative Lung Cancer Treatment - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewswire

Jun 30, 2025
pulisher
Jun 28, 2025

HUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street Zen - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

Rhumbline Advisers Has $50,000 Position in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) - Defense World

Jun 27, 2025
pulisher
Jun 14, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Bought by Bank of America Corp DE - Defense World

Jun 14, 2025
pulisher
Jun 07, 2025

Public Employees Retirement System of Ohio Has $39,000 Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Two Sigma Investments LP Sells 12,471 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise

Jun 05, 2025
pulisher
Jun 05, 2025

Market news - investments.halifax.co.uk

Jun 05, 2025
pulisher
Jun 04, 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 04, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 01, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 26, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 24, 2025
pulisher
May 20, 2025

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 20, 2025
pulisher
May 16, 2025

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 16, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

May 16, 2025
pulisher
May 15, 2025

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

May 15, 2025
pulisher
May 13, 2025

International companies to host live webcasts at Deutsche - GlobeNewswire

May 13, 2025
pulisher
May 06, 2025

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

May 05, 2025
pulisher
Apr 29, 2025

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

Apr 29, 2025
pulisher
Apr 23, 2025

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

Apr 21, 2025
pulisher
Mar 24, 2025

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

Mar 24, 2025
pulisher
Mar 23, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Mar 23, 2025
pulisher
Mar 20, 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

Mar 18, 2025

Hutchmed China Limited Adr (HCM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.25
price up icon 0.93%
$18.49
price up icon 3.30%
drug_manufacturers_specialty_generic RDY
$14.24
price up icon 0.21%
$10.42
price up icon 0.10%
$138.13
price up icon 0.94%
$305.35
price down icon 1.25%
大文字化:     |  ボリューム (24 時間):